Tesamorelin + Ipamorelin

Buy Tesamorelin + Ipamorelin Online

Tesamorelin + Ipamorelin combines tesamorelin, a GHRH analogue, with ipamorelin, a selective growth hormone secretagogue. The combination is designed around two complementary mechanisms for stimulating growth hormone secretion.

Product Information

Tesamorelin has established clinical research involving GH and IGF-1 signaling, while Ipamorelin has been investigated as a selective GH secretagogue. However, there is currently no published controlled trial specifically evaluating the tesamorelin + ipamorelin combination. Evidence from each compound should therefore remain separate.

How It Works

Tesamorelin activates the GHRH pathway, while Ipamorelin activates the growth hormone secretagogue receptor. Both pathways influence pituitary GH secretion, providing the rationale for studying their combined effects.

POTENTIAL BENEFITS

1. Growth Hormone Research

Tesamorelin has demonstrated significant effects on GH and IGF-1 signaling in clinical research. Ipamorelin adds a distinct secretagogue pathway, making the combination relevant to GH-axis investigations.

2. IGF-1 Research

Tesamorelin increases circulating IGF-1 through stimulation of endogenous GH secretion. This provides a well-characterized downstream marker for research involving the GH axis.

3. Body-Composition Research

Tesamorelin has been clinically studied in relation to visceral adipose tissue and body composition. The combination with Ipamorelin is marketed around similar GH-axis research, although the combined formulation itself has not been clinically evaluated.

4. Endocrine Signaling Research

Using a GHRH analogue together with a GH secretagogue provides a model for studying how separate stimulatory signals converge on pituitary GH secretion.

Dosage

There is no established dosage for the Tesamorelin + Ipamorelin combination. Tesamorelin has been clinically studied at 2 mg once daily in its approved formulation, while Ipamorelin has separate experimental dosing data. These should not be combined into a self-directed dosing protocol.

Side Effects

GH-axis stimulation can produce headache, injection-site reactions, fluid retention, joint discomfort, and changes in glucose metabolism. Tesamorelin can also increase IGF-1, requiring monitoring in clinical use.

References

1. Review of Tesamorelin + Ipamorelin research evidence
2. Tesamorelin effects on visceral adipose tissue — PubMed
3. Tesamorelin and GH/IGF-1 signaling — PubMed
4. Ipamorelin clinical research — PubMed

Note: BehemothLabz does not sell this product. Purchase links on this page may direct you to third-party suppliers through affiliate links.

Please click here to see how purchases actually work on this site.